RNA-based therapeutics hold significant potential as promising
|
|
- Marsha McLaughlin
- 8 years ago
- Views:
Transcription
1 Supplement to the May 2011 Issue of pharmtech.com 2011 The Industry s Authoritative Source MicroRNA Therapeutics Perspectives in MicroRNA Therapeutics Kevin Steffy, Charles Allerson, and Balkrishen Bhat Decades of research and development have produced a rich, deep pipeline of preclinical and clinical programs based on oligonucleotide therapeutics. In particular, anti-mir therapeutics represent an exciting opportunity in the field of microrna drug discovery. The authors provide further insight into microrna biology, and the simplicity of anti-mir oligonucleotide drug delivery, which can restore balance and function to dysregulated microrna pathways of gene expression. Kevin Steffy, PhD,* is the global alliance manager, Charles Allerson, PhD, is the associate director of chemistry, and Balkrishen Bhat, PhD, is the senior director of chemistry, all at Regulus Therapeutics, 3545 John Hopkins Ct., San Diego, CA 92121, tel , ksteffy@regulusrx.com. *To whom all correspondence should be addressed. RNA-based therapeutics hold significant potential as promising treatment options for human disease. In the past 20 years, advances in the RNA field have identified several novel RNAbased therapies that are currently under clinical investigation, including antisense oligonucleotides, small interfering RNA (sirna), and microrna. By targeting RNA and modulating human biology at the molecular level, these new technologies have allowed drug-discovery efforts to focus on a broad range of disease targets once deemed to be undruggable. Leading RNA biotechnology companies have since expanded the target space and generated multiple clinical candidates characterized by improved target specificity, improved drug safety, and demonstrated efficacy in patients. These companies have traditionally focused on targeting specific genes relevant to the disease indication through the control of protein synthesis at the RNA level. More recently, drug discovery researchers are attempting to regulate entire networks of genes through the modulation of a single microrna. Targeting micrornas with either oligonucleotide inhibitors, namely anti-mirs, or mir-mimics (doublestranded oligonucleotides that replace microrna function), provides a novel class of therapeutics and a unique approach to treating disease by modulating entire biological pathways (see Figure 1). Targeting specific genes using antisense oligonucleotides and sirna Antisense oligonucleotides and sirna have great potential to become mainstream therapeutic entities. This is due, in part, to their high specificity and wide therapeutic target space in the genome. The antisense approach targets a specific gene and interrupts the translation phase of the protein production process by preventing the mrna from reaching the ribosome (1). Antisense drugs are short (15 23mer) chemically modified nucleotide chains that hybridize to a specific complementary area of mrna. On hybridization, the mrna is recognized as a RNA- DNA hybrid and degraded through an RNase H cleavage mechanism and not translated by the ribosome into a functional protein (see Figure 2). By inhibiting the production of proteins involved in disease, antisense drugs can create pharmacologic benefit for patients.
2 MicroRNA Therapeutics Figure 1: The RNA therapeutics opportunity. MicroRNAs represent a new set of drug targets capable of regulating an entire network of related genes. Figure 2: MicroRNAs are key regulators of the genome. Hybridization of micrornas (red) to their target seed sequence in mrnas regulates and directs the expression of an entire network of genes. AGO is Argonaute protein, DGCR8 is DiGeorge critical region 8, mir is microrna, RISC is RNA induced silencing complex. RNA interference (RNAi) is a highly conserved sequence-dependent eukaryotic process for regulating gene expression. Small stretches of double-stranded RNA ranging from 19 to 25 base pairs, and known as sirna, utilize the RNA induced silencing complex (RISC) pathway to target a specific gene and bind to its homologous mrna. This results in site-specific mrna cleavage and protein degradation (see Table I) (2). The presence of the RNAi cellular components, combined with silencing, specificity, and efficacy makes it an attractive mechanism for targeting dysregulated gene expression in human disease. Targeting gene pathways using microrna therapeutics More than 750 micrornas have been identified to date, regulating an estimated one-third of all human genes (3). Using sophisticated bioinformatics analyses and enhanced detection methodologies, scientists demonstrated that a single microrna may be capable of regulating hundreds of messenger RNAs that function in the same or related pathways. Because micrornas have functions in multiple biological pathways, a change in expression or function of micror- NAs might give rise to diseases, such as cancer, fibrosis, metabolic disorders and inflammatory disorders. The demonstration that several micrornas are up-regulated in a particular disease phenotype provides the rationale to use anti-mir technology to restore the balance of normal gene regulation inside the cell (see Table I) (4). Introduction to micrornas MicroRNAs are small noncoding RNAs that are approximately nucleotides in length. They regulate expression of multiple target genes through sequence-specific hybridization to the 3 untranslated region (UTR) of messenger RNAs and block either translation or direct degradation of their target messenger RNAs (5). MicroRNA genes are expressed in the cell nucleus as a precursor called the primary microrna which, upon further processing by an enzyme called Drosha, lead to pre-microrna (see Figure 2). Once exported into the cytoplasm, the pre-microrna is cleaved by the Dicer enzyme into a nucleotide-long double-stranded RNA that is then loaded into RISC. This process is followed by the unwinding of the two RNA strands, the degradation of the passenger strand, and the retention of the mature microrna. Through the RISC, the microrna guides and targets messenger RNAs through direct base pairing. The 5 region of microrna, also known as the seed region (nucleotides 1 through 8 or 2 through 9), is the most critical sequence for targeting and function (6). The microrna target sites, located in the 3 UTR of messenger RNAs, are often imperfectly matched to the microrna sequence. MicroRNAs do not require perfect complementarity for target recognition, so a single microrna is able to regulate multiple messenger RNAs. Although micrornas exert subtle effects on each individual messenger RNA target, the combined effect is significant and produces measurable phenotypic results. The ability of micrornas to influence an entire network of genes involved in a common cellular process provides tremendous therapeutic potential and differs from the specificity of today s drugs, which act on specific cellular targets. MicroRNAs play integral roles in several biological processes, including immune modulation, metabolic control, neuronal development, cell cycle, muscle differentiation, and stem-cell differentiation. Most micrornas are conserved across multiple animal species, indicating the evolutionary importance of these molecules as modulators of critical biological pathways and processes (3). Anti-miR therapeutics The association of microrna dysfunction with disease has created enormous potential for selective modulation of micrornas using anti-mir oligonucleotides, which are rationally designed and chemically modified to enhance target affinity, stability, and tissue uptake. Aberrantly expressed or mutated micrornas that cause significant changes in critical biological pathways represent poten- ALL FIGURES COURTESY OF THE AUTHORS 2 Pharmaceutical Technology BIOPROCESSING & STERILE MFG PharmTech.com
3 Table I: Overview of the current RNA-based drug-discovery platform. Technology Compound Target Delivery Mechanism Regulus microrna platform sirna ASO Single stranded anti-mirs (15-19nt) Double-stranded mir-mimics (21-23bp) Double-stranded RNAs (22bp) Single-stranded oligos (15-20nt, gapmer) micrornas No DDS for anti-mirs DDS required for mimics (single strand mimic in process) microrna targeting leads to pathway modulation messenger RNA DDS required Cleavage of a single mrna by RISC/AGO2 messenger RNA No DDS Cleavage of a single mrna in nucleus by RNase H tial targets whose selective modulation could alter the course of disease. From a mechanistic view, the inhibition of the microrna target is based on the specific annealing of the anti-mir (see Figure 3). A stable, high-affinity bond between the anti-mir and the microrna will compete with binding to the 3 UTR target region. Studies by Regulus Therapeutics and others have demonstrated that modulating micrornas through anti-mir oligonucleotides can effectively regulate biological processes and produce therapeutically beneficial results in murine models of cardiac dysfunction; reducing cancer metastases in murine tumor models; and reducing viral load in the chimpanzee model of hepatitis C virus infection (7,8,9). Most recently, advances in oligonucleotide chemistry have improved potency and stability by modification with novel 2,4 -constrained 2 O-ethyl (cet) nucleotides (). The ability to achieve increased inhibitory potency with this next generation of bicyclic nucleic acid chemistry could make a significant positive impact on the design of anti-mir inhibitors for a vast array of microrna disease targets. Anti-miR oligonucleotide drug delivery Up until nearly a decade ago, insufficient in vivo stability, limited methods of delivery and tissue distribution of oligonucleotides hampered successful clinical development for several promising oligonucleotide therapeutic agents. As high molecular weight, highly charged polyanionic molecules, oligonucleotides faced many hurdles in reaching their target organ or target cell type. First-generation antisense phosphorothiolated oligodeoxynucleotide clinical candidates administered into the bloodstream had a low affinity for their target, poor stability because of nuclease degradation, unfavorable immunostimulatory properties, and rapid excretion by renal clearance, resulting in shortened half-lives (11). To increase their metabolic stability and tissue half-life, antisense and anti-mir oligonucleotides from second-generation nucleoside chemistries were developed that dramatically altered the pharmacokinetic properties of these molecules (,12). The introduction of chemical modifications such as 2 methoxyethyl (MOE) and 2, 4 -constrained 2 O-ethyl (cet) into the ribose sugar ring significantly improved both the pharmacokinetic and safety profile of antisense oligonucleotides. Once delivered systemically, these second-generation compounds rapidly partition from the plasma and are taken up by cells of multiple tissues without the need of formulation or a delivery vehicle. Benefitting from nearly 20 years of oligonucleotide chemistry advances at companies such as Isis Pharmaceuticals, leading developers of anti-mir therapies have garnered a tremendous advantage in improved delivery strategies. The high water solubility of anti-mir oligonucleotides due to their polyanionic chemical structure has allowed anti-mir formulation in simple aqueous solutions such as buffered saline (13). The only limiting factor is the viscosity of the solution, which is generally concentration-dependent for single-stranded oligonucleotides (13). This simple anti-mir formulation is in contrast to the requirements for double-stranded sirna drug delivery, which must fully encapsulate the sirna in a lipid nanoparticle to systemically deliver its contents to a target tissue (14). Anti-miR route of administration and tissue distribution Bioavailability and tissue distribution of anti-mirs have been studied extensively in rodents and nonhuman primates. The preferred route of administration for most therapeutic anti-mir compounds is subcutaneous systemic delivery, because it provides efficient dissemination of the drug to different tissues including the liver, kidney and adipose tissue without the need of a drug delivery system. Additionally, the biodistribution of anti-mirs in multiple animal species following subcutaneous administration provides valuable information Figure 3: Single-stranded oligonucleotide anti-mirs pharmacologically modulate dysregulated micrornas. The anti-mir oligonucleotide (black) binds and hybridizes to the abnormally expressed microrna (red), blocking its function within the cell. DGCR8 is DiGeorge critical region, and mir is microrna. Pharmaceutical Technology BIOPROCESSING & STERILE MFG
4 MicroRNA Therapeutics regarding organs that may be successfully treated, as well as those organs unlikely to be affected. Multiple studies were performed in mice and monkeys with second generation anti-mir 1 and anti-mir 2 compounds given subcutaneously once weekly over several weeks. A quantitative analysis of tissues demonstrated broad biodistribution of modified anti-mirs among multiple tissue types including the kidney, liver, lymph nodes, adipose tissue, and spleen, as demonstrated by mass spectrometry analysis (see Figure 4). These organs have been previously shown to be target sites for oligonucleotide distribution after parenteral administration (13). Additionally, the similar pharmacokinetics and correlated tissue distribution of each anti-mir in different preclinical animal models provide important guidance for selection of different disease indications and may assist in better clinical trial designs with anti-mir therapies (see Figure 5). Effective delivery of anti-mir oligonucleotides has also been demonstrated in different species through multiple routes of administration including: intravenous, intraperitoneal, intratracheal, intranasal, and intracerebral. A more detailed analysis of anti-mir tissue distribution using quantitative whole body autoradiography to provide additional quantitative information is in progress. Anti-miR delivery and function mrna expression profiling methods coupled with statistical techniques that can measure small changes in the expression of many genes have become powerful tools to further our understanding of the biological role and function of micrornas. Relying on the scientific findings that some micrornas are capable of regulating hundreds of messenger RNAs, studies were performed in mice to determine anti-mir delivery to different cell types. Mice were treated with a specific anti-mir (intraperitoneal injection) and multiple cell types were harvested to for mrna expression studies using Sylamer enrichment analysis (15). Anti-miR oligonucleotides are distributed to peritoneal macrophages as evidenced by flow cytometry analysis and target gene up-regulation (see Figure 6). An analysis identifying an overrepresented set of genes associated with a specific anti-mir biological effect was conducted and a data plot from the isolated macrophages was generated that demonstrated the most up-regulated sets of genes after anti-mir treatment. P values generated for this dataset suggest statistically significant preferential up-regulation of genes matched to their target sequence after anti-mir treatment. Conclusion Targeting pathways of human disease with microrna-based drugs represents a novel and potentially powerful therapeutic approach. Recent data demonstrate not only that dysregulated micrornas are associated with and can cause human disease, but that selective modulation through anti-mir intervention can provide therapeutic benefits. Anti-miR oligonucleotides can be easily administered through local or parenteral injection routes with sufficient uptake of the agent to achieve sustained target inhibition in tissues and organs without the need of formulation. Improvements in antimir chemical design and pharmacokinetic properties will allow further exploration of microrna biology and broaden the utility of microrna therapeutics. Figure 4: Similar pattern of tissue distribution for chemically modified anti-mirs in mouse and monkey. Anti-miR oligonucleotide quantitation was performed on tissues by either mass spectrometry analysis or capillary gel electrophoresis. IP is Intraperitoneal, SC is subcutaneous. ug Anti-miR/g tissue (μm) Mouse kidney Intestine Muscle Lymph 34 mg/kg/week delivered IP for 3 weeks References 1. S.T. Crooke et al., Mechanisms of Antisense Drug Action, an Introduction, in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, Ed. (CRC Press, Boca Raton, 2007), pp S.M. Elbashir et al., Nature 411 (6386), (2001). 3. A. Jackson and P.S. Linsley, Discovery Medicine 9 (47), (20). 4. J. Krutzfeldt et al., Nature 438 (7068), (2005). 5. D.P. Bartel, Cell 116 (2), (2004). 6. E.C. Lai, Nat. Rev. Genet 30 (4), (2002). 7. T. Thum et al., Nature 456 (7224), (2008). 8. L. Ma et al., Nature 28 (4), (20) Monkey kidney Lymph nodes Bone marrow 25 mg/kg/week delivered SC for 6 weeks Figure 5: The distributions of anti-mirs in mice and monkey are highly correlated. Quantitative analysis of drug concentration by mass spectrometry revealed a good correlation of drug tissue distribution across multiple species. Monkey drug levels (μg/g) Monkey Vs. Mouse Lymph Mouse drug levels (μg/g) Anti-mR 1 Anti-mR 2 Kidney Pharmaceutical Technology BIOPROCESSING & STERILE MFG PharmTech.com
5 Figure 6: Functional drug delivery of anti-mirs in mouse peritoneal macrophages. Flow-cytometry studies (a) and gene-regulation studies (b) demonstrate the internalization of anti-mir and target engagement in macrophages (Sylamer analysis). Potential targets containing heptamer 1-7 (GCATTAA) or heptamer 2-8 (AGCATTA) are enriched. X-axis is ranked genes by fold change. Y axis is -log (P-value enrichment). PBS is Phosphatebuffered saline. (a) PBS Anti-miR-Cy (b) 3 - UGGGGAUAGUGUUAAUCGUAAUU-5 CD11b MFI Cy log Enrichment P-value GCATTAA AGCATTA Target cell Sorted sequences (most up- to most down-regulated) Messenger RNA 9. R.E. Lanford et al., Science 327 (5962), (20).. P.P. Seth et al., J. Med. Chem. 52 (1), 13 (2009). 11. A.A. Levin, R. Zu, and R.S. Geary, Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs, in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, Ed. (CRC Press, Boca Raton, 2007), pp B. Monia et al. J. Biol. Chem. 268 (19), (1993). 13. R.S. Geary, R. Zu, and A.A. Levin, Pharmacokinetic/Pharmacodynamic Properties of Phosphorothioate 2 -O-(2-Methoxyethyl)-Modified Antisense Oligonucleotides in Animals and Man, in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, Ed. (CRC Press, Boca Raton, 2007), pp S.C. Semple et al., Nature Biotech. 28 (2), (20). 15. S.V. Dongen et al., Nature Methods 5 (12) (2008). PT Posted with permission from the May 2011 Supplement to Pharmaceutical Technology. Copyright 2011, an Advanstar publication. All rights reserved. # Managed by The YGS Group, For more information visit
Gene Silencing Oligos (GSOs) Third Generation Antisense
Gene Silencing Oligos (GSOs) Third Generation Antisense Walter R. Strapps, Ph.D. Executive Director, RNA Therapeutics Idera Pharmaceuticals Cambridge, MA NASDAQ: IDRA www.iderapharma.com Idera is a leader
More informationDicer Substrate RNAi Design
INTEGRATED DNA TECHNOLOGIES, INC. Dicer Substrate RNAi Design How to design and order 27-mer Dicer-substrate Duplex RNAs for use as RNA interference reagents The following document provides a summary of
More informationRNAi Shooting the Messenger!
RNAi Shooting the Messenger! Bronya Keats, Ph.D. Department of Genetics Louisiana State University Health Sciences Center New Orleans Email: bkeats@lsuhsc.edu RNA interference (RNAi) A mechanism by which
More informationThe world of non-coding RNA. Espen Enerly
The world of non-coding RNA Espen Enerly ncrna in general Different groups Small RNAs Outline mirnas and sirnas Speculations Common for all ncrna Per def.: never translated Not spurious transcripts Always/often
More informationTOOLS sirna and mirna. User guide
TOOLS sirna and mirna User guide Introduction RNA interference (RNAi) is a powerful tool for suppression gene expression by causing the destruction of specific mrna molecules. Small Interfering RNAs (sirnas)
More information岑 祥 股 份 有 限 公 司 技 術 專 員 費 軫 尹 20100803
技 術 專 員 費 軫 尹 20100803 Overview of presentation Basic Biology of RNA interference Application of sirna for gene function? How to study mirna? How to deliver sirna and mirna? New prospects on RNAi research
More informationOutline. interfering RNA - What is dat? Brief history of RNA interference. What does it do? How does it work?
Outline Outline interfering RNA - What is dat? Brief history of RNA interference. What does it do? How does it work? What is RNA interference? Recently discovered regulatory level. Genome immune system.
More informationMicro RNAs: potentielle Biomarker für das. Blutspenderscreening
Micro RNAs: potentielle Biomarker für das Blutspenderscreening micrornas - Background Types of RNA -Coding: messenger RNA (mrna) -Non-coding (examples): Ribosomal RNA (rrna) Transfer RNA (trna) Small nuclear
More informationJust the Facts: A Basic Introduction to the Science Underlying NCBI Resources
1 of 8 11/7/2004 11:00 AM National Center for Biotechnology Information About NCBI NCBI at a Glance A Science Primer Human Genome Resources Model Organisms Guide Outreach and Education Databases and Tools
More informationMicroRNA formation. 4th International Symposium on Non-Surgical Contraceptive Methods of Pet Population Control
MicroRNA formation mirna s are processed from several precursor stages Mammalian genomes seem to have 100 s of mirna s Nucleotides in positions 2-8 of an mirna are considered the mirna seed 5 Methyl-G
More informationPART 3.3: MicroRNA and Cancer
BIBM 2010 Tutorial: Epigenomics and Cancer PART 3.3: MicroRNA and Cancer Dec 18, 2010 Sun Kim at Indiana University Outline of Part 3.3 Background on microrna Role of microrna in cancer MicroRNA pathway
More information13.4 Gene Regulation and Expression
13.4 Gene Regulation and Expression Lesson Objectives Describe gene regulation in prokaryotes. Explain how most eukaryotic genes are regulated. Relate gene regulation to development in multicellular organisms.
More informationMicroRNA Mike needs help to degrade all the mrna transcripts! Aaron Arvey ISMB 2010
Target mrna abundance dilutes microrna and sirna activity MicroRNA Mike needs help to degrade all the mrna transcripts! Aaron Arvey ISMB 2010 Target mrna abundance dilutes microrna and sirna activity Erik
More informationControl of Gene Expression
Control of Gene Expression What is Gene Expression? Gene expression is the process by which informa9on from a gene is used in the synthesis of a func9onal gene product. What is Gene Expression? Figure
More informationFive-year relative survival rates. Cancer. Age-adjusted cancer death rates. Proteomic Technologies for Cancer Biomarker Discovery 2010/3/22
Cancer Five-year relative survival rates Basal lamina Underlyig tissue Normal tissue Carcinoma Invasive carcinoma 1 http://www.cancer.org/docroot/home/index.asp 2 Proteomic Technologies for Cancer Biomarker
More informationV22: involvement of micrornas in GRNs
What are micrornas? V22: involvement of micrornas in GRNs How can one identify micrornas? What is the function of micrornas? Elisa Izaurralde, MPI Tübingen Huntzinger, Izaurralde, Nat. Rev. Genet. 12,
More informationINSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance
A. Bernheim Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance OVER-MyR is funded by the European Commission within its FP7 specific
More informationName Date Period. 2. When a molecule of double-stranded DNA undergoes replication, it results in
DNA, RNA, Protein Synthesis Keystone 1. During the process shown above, the two strands of one DNA molecule are unwound. Then, DNA polymerases add complementary nucleotides to each strand which results
More informationTranscription and Translation of DNA
Transcription and Translation of DNA Genotype our genetic constitution ( makeup) is determined (controlled) by the sequence of bases in its genes Phenotype determined by the proteins synthesised when genes
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationSchool of Nursing. Presented by Yvette Conley, PhD
Presented by Yvette Conley, PhD What we will cover during this webcast: Briefly discuss the approaches introduced in the paper: Genome Sequencing Genome Wide Association Studies Epigenomics Gene Expression
More informationRNAi: principle DNA RNA PROTEIN
RNAi: principle RNAi DNA RNA PROTEIN Transcription (nucleus) Translation (cytoplasm) Many diseases develop from the undesirable production of specific proteins (oncogene products, mutant proteins, toxins,
More informationLezioni Dipartimento di Oncologia Farmacologia Molecolare. RNA interference. Giovanna Damia 29 maggio 2006
Lezioni Dipartimento di Oncologia Farmacologia Molecolare RNA interference Giovanna Damia 29 maggio 2006 RNA INTERFERENCE Sequence-specific gene suppression by dsrnas Gene silencing by dsrna: C. elegans
More informationOutline. MicroRNA Bioinformatics. microrna biogenesis. short non-coding RNAs not considered in this lecture. ! Introduction
Outline MicroRNA Bioinformatics Rickard Sandberg Dept. of Cell and Molecular Biology (CMB) Karolinska Institutet! Introduction! microrna target site prediction! Useful resources 2 short non-coding RNAs
More informationThe RNA strategy. RNA as a tool and target in human disease diagnosis and therapy.
The RNA strategy RNA as a tool and target in human disease diagnosis and therapy. The Laboratory of RNA Biology and Biotechnology at the Centre for Integrative Biology (CIBIO) of the University of Trento,
More informationCCR Biology - Chapter 9 Practice Test - Summer 2012
Name: Class: Date: CCR Biology - Chapter 9 Practice Test - Summer 2012 Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Genetic engineering is possible
More informationFunctional and Biomedical Aspects of Genome Research
Functional and Biomedical Aspects of Genome Research 20 11 35 Vorlesung SS 04 Bartsch, Jockusch & Schmitt-John Mi. 9:15-10:00, in W7-135 13 Functional RNAs Thomas Schmitt-John micro RNAs small interfering
More informationGene mutation and molecular medicine Chapter 15
Gene mutation and molecular medicine Chapter 15 Lecture Objectives What Are Mutations? How Are DNA Molecules and Mutations Analyzed? How Do Defective Proteins Lead to Diseases? What DNA Changes Lead to
More informationTHE ENZYMES. Department of Microbiology, Immunology, and Molecular Genetics, Molecular Biology Institute University of California
VOLUME THIRTY TWO THE ENZYMES Eukaryotic RNases and their Partners in RNA Degradation and Biogenesis, Part B Edited by FENG GUO Department of Biological Chemistry, David Geffen School of Medicine, Molecular
More informationLecture Series 7. From DNA to Protein. Genotype to Phenotype. Reading Assignments. A. Genes and the Synthesis of Polypeptides
Lecture Series 7 From DNA to Protein: Genotype to Phenotype Reading Assignments Read Chapter 7 From DNA to Protein A. Genes and the Synthesis of Polypeptides Genes are made up of DNA and are expressed
More informationTECHNICAL INSIGHTS TECHNOLOGY ALERT
TECHNICAL INSIGHTS TECHNOLOGY ALERT UNLOCKING BREAST CANCER TUMORS' DRUG RESISTANCE A troubling phenomenon in breast cancer treatment is that some patients tumors become resistant to treatments over time.
More informationControl of Gene Expression
Control of Gene Expression (Learning Objectives) Explain the role of gene expression is differentiation of function of cells which leads to the emergence of different tissues, organs, and organ systems
More informationDNA Replication & Protein Synthesis. This isn t a baaaaaaaddd chapter!!!
DNA Replication & Protein Synthesis This isn t a baaaaaaaddd chapter!!! The Discovery of DNA s Structure Watson and Crick s discovery of DNA s structure was based on almost fifty years of research by other
More informationExpert Intelligence for Better Decisions. MicroRNA: An Insight to mirna-based Microarrays, Diagnostics and Therapeutics
Expert Intelligence for Better Decisions MicroRNA: An Insight to mirna-based Microarrays, Diagnostics and Therapeutics Using This Document Insight Pharma Reports are interactive electronic documents which
More informationGene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More informationCHAPTER 40 The Mechanism of Protein Synthesis
CHAPTER 40 The Mechanism of Protein Synthesis Problems: 2,3,6,7,9,13,14,15,18,19,20 Initiation: Locating the start codon. Elongation: Reading the codons (5 3 ) and synthesizing protein amino carboxyl.
More informationBasic Concepts of DNA, Proteins, Genes and Genomes
Basic Concepts of DNA, Proteins, Genes and Genomes Kun-Mao Chao 1,2,3 1 Graduate Institute of Biomedical Electronics and Bioinformatics 2 Department of Computer Science and Information Engineering 3 Graduate
More informationFrom DNA to Protein. Proteins. Chapter 13. Prokaryotes and Eukaryotes. The Path From Genes to Proteins. All proteins consist of polypeptide chains
Proteins From DNA to Protein Chapter 13 All proteins consist of polypeptide chains A linear sequence of amino acids Each chain corresponds to the nucleotide base sequence of a gene The Path From Genes
More informationSummary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs
Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer
More informationGuidance for Industry Safety Testing of Drug Metabolites
Guidance for Industry Safety Testing of Drug Metabolites U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2008 Pharmacology
More informationName Class Date. Figure 13 1. 2. Which nucleotide in Figure 13 1 indicates the nucleic acid above is RNA? a. uracil c. cytosine b. guanine d.
13 Multiple Choice RNA and Protein Synthesis Chapter Test A Write the letter that best answers the question or completes the statement on the line provided. 1. Which of the following are found in both
More informationProfiling of non-coding RNA classes Gunter Meister
Profiling of non-coding RNA classes Gunter Meister RNA Biology Regensburg University Universitätsstrasse 31 93053 Regensburg Overview Classes of non-coding RNAs Profiling strategies Validation Protein-RNA
More informationmirnaselect pep-mir Cloning and Expression Vector
Product Data Sheet mirnaselect pep-mir Cloning and Expression Vector CATALOG NUMBER: MIR-EXP-C STORAGE: -80ºC QUANTITY: 2 vectors; each contains 100 µl of bacterial glycerol stock Components 1. mirnaselect
More informationHemophilia Care. Will there always be new people in the world with hemophilia? Will hemophilia be treated more effectively and safely in the future?
Future of This chapter provides answers to these questions: Will there always be new people in the world with hemophilia? Will hemophilia be treated more effectively and safely in the future? Will the
More informationALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES
ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,
More informationSickle cell anemia: Altered beta chain Single AA change (#6 Glu to Val) Consequence: Protein polymerizes Change in RBC shape ---> phenotypes
Protein Structure Polypeptide: Protein: Therefore: Example: Single chain of amino acids 1 or more polypeptide chains All polypeptides are proteins Some proteins contain >1 polypeptide Hemoglobin (O 2 binding
More informationOriGene Technologies, Inc. MicroRNA analysis: Detection, Perturbation, and Target Validation
OriGene Technologies, Inc. MicroRNA analysis: Detection, Perturbation, and Target Validation -Optimal strategies to a successful mirna research project Optimal strategies to a successful mirna research
More informationEssentials of Real Time PCR. About Sequence Detection Chemistries
Essentials of Real Time PCR About Real-Time PCR Assays Real-time Polymerase Chain Reaction (PCR) is the ability to monitor the progress of the PCR as it occurs (i.e., in real time). Data is therefore collected
More informationDNA and the Cell. Version 2.3. English version. ELLS European Learning Laboratory for the Life Sciences
DNA and the Cell Anastasios Koutsos Alexandra Manaia Julia Willingale-Theune Version 2.3 English version ELLS European Learning Laboratory for the Life Sciences Anastasios Koutsos, Alexandra Manaia and
More informationControl of Gene Expression
Home Gene Regulation Is Necessary? Control of Gene Expression By switching genes off when they are not needed, cells can prevent resources from being wasted. There should be natural selection favoring
More informationLuca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
More informationRecombinant DNA and Biotechnology
Recombinant DNA and Biotechnology Chapter 18 Lecture Objectives What Is Recombinant DNA? How Are New Genes Inserted into Cells? What Sources of DNA Are Used in Cloning? What Other Tools Are Used to Study
More informationThe Steps. 1. Transcription. 2. Transferal. 3. Translation
Protein Synthesis Protein synthesis is simply the "making of proteins." Although the term itself is easy to understand, the multiple steps that a cell in a plant or animal must go through are not. In order
More informationDiabetes and Drug Development
Diabetes and Drug Development Metabolic Disfunction Leads to Multiple Diseases Hypertension ( blood pressure) Metabolic Syndrome (Syndrome X) LDL HDL Lipoproteins Triglycerides FFA Hyperinsulinemia Insulin
More informationAnalyzing microrna Data and Integrating mirna with Gene Expression Data in Partek Genomics Suite 6.6
Analyzing microrna Data and Integrating mirna with Gene Expression Data in Partek Genomics Suite 6.6 Overview This tutorial outlines how microrna data can be analyzed within Partek Genomics Suite. Additionally,
More informationDicer-Substrate sirna Technology
As featured in BioRadiations 120 Dicer-Substrate sirna Technology Advances in sirna Designs Improve Gene-Specific Silencing Steve Kulisch, Teresa Esch, Christina Whitman-Guliaev, and Teresa Rubio, Bio-Rad
More informationTranslation Study Guide
Translation Study Guide This study guide is a written version of the material you have seen presented in the replication unit. In translation, the cell uses the genetic information contained in mrna to
More informationBiochemistry Major Talk 2014-15. Welcome!!!!!!!!!!!!!!
Biochemistry Major Talk 2014-15 August 14, 2015 Department of Biochemistry The University of Hong Kong Welcome!!!!!!!!!!!!!! Introduction to Biochemistry A four-minute video: http://www.youtube.com/watch?v=tpbamzq_pue&l
More informationRNA & Protein Synthesis
RNA & Protein Synthesis Genes send messages to cellular machinery RNA Plays a major role in process Process has three phases (Genetic) Transcription (Genetic) Translation Protein Synthesis RNA Synthesis
More information19. Drug Treatment Trials
1 9. D R U G T R E A T M E N T T R I A L S 19. Drug Treatment Trials The science behind the Progeria clinical drug trials Trial medications at a glance Progeria clinical drug trials The science behind
More informationCHAPTER 6: RECOMBINANT DNA TECHNOLOGY YEAR III PHARM.D DR. V. CHITRA
CHAPTER 6: RECOMBINANT DNA TECHNOLOGY YEAR III PHARM.D DR. V. CHITRA INTRODUCTION DNA : DNA is deoxyribose nucleic acid. It is made up of a base consisting of sugar, phosphate and one nitrogen base.the
More informationHUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE
HUNTINGTON S DISEASE MULTIDISCIPLINARY CLINIC HUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE From gene to treatments The gene that causes Huntington s disease (HD) was discovered in 1993. Since then, enormous
More informationSystematic discovery of regulatory motifs in human promoters and 30 UTRs by comparison of several mammals
Systematic discovery of regulatory motifs in human promoters and 30 UTRs by comparison of several mammals Xiaohui Xie 1, Jun Lu 1, E. J. Kulbokas 1, Todd R. Golub 1, Vamsi Mootha 1, Kerstin Lindblad-Toh
More informationa. Ribosomal RNA rrna a type ofrna that combines with proteins to form Ribosomes on which polypeptide chains of proteins are assembled
Biology 101 Chapter 14 Name: Fill-in-the-Blanks Which base follows the next in a strand of DNA is referred to. as the base (1) Sequence. The region of DNA that calls for the assembly of specific amino
More informationFACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company
More informationDNA, RNA, Protein synthesis, and Mutations. Chapters 12-13.3
DNA, RNA, Protein synthesis, and Mutations Chapters 12-13.3 1A)Identify the components of DNA and explain its role in heredity. DNA s Role in heredity: Contains the genetic information of a cell that can
More informationGenetics Module B, Anchor 3
Genetics Module B, Anchor 3 Key Concepts: - An individual s characteristics are determines by factors that are passed from one parental generation to the next. - During gamete formation, the alleles for
More informationUnderstanding the immune response to bacterial infections
Understanding the immune response to bacterial infections A Ph.D. (SCIENCE) DISSERTATION SUBMITTED TO JADAVPUR UNIVERSITY SUSHIL KUMAR PATHAK DEPARTMENT OF CHEMISTRY BOSE INSTITUTE 2008 CONTENTS Page SUMMARY
More informationRNA and Protein Synthesis
Name lass Date RN and Protein Synthesis Information and Heredity Q: How does information fl ow from DN to RN to direct the synthesis of proteins? 13.1 What is RN? WHT I KNOW SMPLE NSWER: RN is a nucleic
More informationStructure and Function of DNA
Structure and Function of DNA DNA and RNA Structure DNA and RNA are nucleic acids. They consist of chemical units called nucleotides. The nucleotides are joined by a sugar-phosphate backbone. The four
More informationStudy Partner/Essential Study Partner (ESP): http://highered.mcgraw-hill.com/sites/0073211877/student_view0/study_partner.html
Course: Anatomy and Physiology Honors Course Number: 2000360 Title: Hole s Human Anatomy and Physiology, 10 th Edition Authors: Shier, Butler, Lewis Publisher: Glencoe/McGraw-Hill Copyright: 2004 Online
More informationChapter 18 Regulation of Gene Expression
Chapter 18 Regulation of Gene Expression 18.1. Gene Regulation Is Necessary By switching genes off when they are not needed, cells can prevent resources from being wasted. There should be natural selection
More information2013 W. H. Freeman and Company. 26 RNA Metabolism
2013 W. H. Freeman and Company 26 RNA Metabolism CHAPTER 26 RNA Metabolism Key topics: Transcription: DNA-dependent synthesis of RNA Capping and splicing: RNA processing Overview of RNA Function Ribonucleic
More informationLecture 1 MODULE 3 GENE EXPRESSION AND REGULATION OF GENE EXPRESSION. Professor Bharat Patel Office: Science 2, 2.36 Email: b.patel@griffith.edu.
Lecture 1 MODULE 3 GENE EXPRESSION AND REGULATION OF GENE EXPRESSION Professor Bharat Patel Office: Science 2, 2.36 Email: b.patel@griffith.edu.au What is Gene Expression & Gene Regulation? 1. Gene Expression
More information12.1 The Role of DNA in Heredity
12.1 The Role of DNA in Heredity Only in the last 50 years have scientists understood the role of DNA in heredity. That understanding began with the discovery of DNA s structure. In 1952, Rosalind Franklin
More informationGenetic information (DNA) determines structure of proteins DNA RNA proteins cell structure 3.11 3.15 enzymes control cell chemistry ( metabolism )
Biology 1406 Exam 3 Notes Structure of DNA Ch. 10 Genetic information (DNA) determines structure of proteins DNA RNA proteins cell structure 3.11 3.15 enzymes control cell chemistry ( metabolism ) Proteins
More informationMolecular Genetics. RNA, Transcription, & Protein Synthesis
Molecular Genetics RNA, Transcription, & Protein Synthesis Section 1 RNA AND TRANSCRIPTION Objectives Describe the primary functions of RNA Identify how RNA differs from DNA Describe the structure and
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationDNA Fingerprinting. Unless they are identical twins, individuals have unique DNA
DNA Fingerprinting Unless they are identical twins, individuals have unique DNA DNA fingerprinting The name used for the unambiguous identifying technique that takes advantage of differences in DNA sequence
More informationHuman Genome Organization: An Update. Genome Organization: An Update
Human Genome Organization: An Update Genome Organization: An Update Highlights of Human Genome Project Timetable Proposed in 1990 as 3 billion dollar joint venture between DOE and NIH with 15 year completion
More informationBSc in Medical Sciences with PHARMACOLOGY
BSc in Medical Sciences with PHARMACOLOGY Course Director Dr Christopher John Module Leaders Dr Robert Dickinson (Module 1) Dr Anabel Varela Carver (Module 2) Dr Sohag Saleh (Module 3) Course Administrator
More informationTo be able to describe polypeptide synthesis including transcription and splicing
Thursday 8th March COPY LO: To be able to describe polypeptide synthesis including transcription and splicing Starter Explain the difference between transcription and translation BATS Describe and explain
More informationA disaccharide is formed when a dehydration reaction joins two monosaccharides. This covalent bond is called a glycosidic linkage.
CH 5 Structure & Function of Large Molecules: Macromolecules Molecules of Life All living things are made up of four classes of large biological molecules: carbohydrates, lipids, proteins, and nucleic
More informationCONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294
AD Award Number: W81XWH-08-1-0030 TITLE: Regulation of Prostate Cancer Bone Metastasis by DKK1 PRINCIPAL INVESTIGATOR: Gregory A. Clines, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Alabama at
More informationFunctional RNAs; RNA catalysts, mirna,
Functional RNAs; RNA catalysts, mirna, srna, RNAi... RNAs have many functions rrna (ribosomal RNA) trna (transfer RNA) mrna (Messenger RNA) snrna (including snorna) ) (Small nuclear RNA- splicing) Other
More informationFACULTY OF MEDICAL SCIENCE
Doctor of Philosophy in Biochemistry FACULTY OF MEDICAL SCIENCE Naresuan University 73 Doctor of Philosophy in Biochemistry The Biochemistry Department at Naresuan University is a leader in lower northern
More informationProtein Synthesis How Genes Become Constituent Molecules
Protein Synthesis Protein Synthesis How Genes Become Constituent Molecules Mendel and The Idea of Gene What is a Chromosome? A chromosome is a molecule of DNA 50% 50% 1. True 2. False True False Protein
More informationMedicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia
Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity
More informationMorpholino, sirna, and S-DNA Compared: Impact of Structure and Mechanism of Action on Off-Target Effects and Sequence Specificity
Current Topics in Medicinal Chemistry, 2007, 7, 651-660 651 Morpholino, sirna, and S-DNA Compared: Impact of Structure and Mechanism of Action on ff-target Effects and Sequence Specificity James E. Summerton*
More informationNucleotides and Nucleic Acids
Nucleotides and Nucleic Acids Brief History 1 1869 - Miescher Isolated nuclein from soiled bandages 1902 - Garrod Studied rare genetic disorder: Alkaptonuria; concluded that specific gene is associated
More informationBasic Overview of Preclinical Toxicology Animal Models
Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background
More informationThe Need for a PARP in vivo Pharmacodynamic Assay
The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235
More informationComplex multicellular organisms are produced by cells that switch genes on and off during development.
Home Control of Gene Expression Gene Regulation Is Necessary? By switching genes off when they are not needed, cells can prevent resources from being wasted. There should be natural selection favoring
More informationDNA (genetic information in genes) RNA (copies of genes) proteins (functional molecules) directionality along the backbone 5 (phosphate) to 3 (OH)
DNA, RNA, replication, translation, and transcription Overview Recall the central dogma of biology: DNA (genetic information in genes) RNA (copies of genes) proteins (functional molecules) DNA structure
More informationCytotoxic and Biotherapies Credentialing Programme Module 2
Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal
More information2. The number of different kinds of nucleotides present in any DNA molecule is A) four B) six C) two D) three
Chem 121 Chapter 22. Nucleic Acids 1. Any given nucleotide in a nucleic acid contains A) two bases and a sugar. B) one sugar, two bases and one phosphate. C) two sugars and one phosphate. D) one sugar,
More informationAdvanced Drug Delivery Reviews
Advanced Drug Delivery Reviews 61 (2009) 746 759 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr sirna vs. shrna: Similarities and
More informationHormones & Chemical Signaling
Hormones & Chemical Signaling Part 2 modulation of signal pathways and hormone classification & function How are these pathways controlled? Receptors are proteins! Subject to Specificity of binding Competition
More informationINDUSTRY OVERVIEW. Our business segments. (ii) Global drug development service market Preclinical drug development services
The information and statistics set out in this section and other sections of this document were extracted from different official government publications, available sources from public market research
More information